Literature DB >> 18694851

Pharmacology of vagal afferent influences on disordered breathing during sleep.

David W Carley1, Miodrag Radulovacki.   

Abstract

Sleep-related breathing disorders (SRBD) are a significant public health concern, with a prevalence in the US general population of approximately 2% of women and approximately 4% of men. Although significant strides have been made in our understanding of these disorders with respect to epidemiology, risk factors, pathogenesis and consequences, work to understand these factors in terms of the underlying cellular, molecular and neuromodulatory processes remains in its infancy. Current primary treatments are surgical or mechanical, with no drug treatments available. Basic investigations into the neurochemistry and neuropharmacology of sleep-related changes in respiratory pattern generation and modulation will be essential to clarify the pathogenic processes underlying SRBD and to identify rational and specific pharmacotherapeutic opportunities. Here we summarize emerging work suggesting the importance of vagal afferent feedback systems in sleep-related respiratory pattern disturbances and pointing toward a rich but complex array of neurochemical and neuromodulatory processes that may be involved.

Entities:  

Mesh:

Year:  2008        PMID: 18694851      PMCID: PMC2642895          DOI: 10.1016/j.resp.2008.06.021

Source DB:  PubMed          Journal:  Respir Physiol Neurobiol        ISSN: 1569-9048            Impact factor:   1.931


  48 in total

1.  Suppression of diaphragmatic activity during spontaneous ponto-geniculo-occipital waves in cat.

Authors:  W L Dunin-Barkowski; J M Orem
Journal:  Sleep       Date:  1998-11-01       Impact factor: 5.849

2.  Maturation of cough and other reflexes that protect the fetal and neonatal airway.

Authors:  Bradley T Thach
Journal:  Pulm Pharmacol Ther       Date:  2006-12-15       Impact factor: 3.410

Review 3.  Neurochemistry of the nodose ganglion.

Authors:  H Zhuo; H Ichikawa; C J Helke
Journal:  Prog Neurobiol       Date:  1997-06       Impact factor: 11.685

4.  The effects of ondansetron on sleep-disordered breathing in the English bulldog.

Authors:  S C Veasey; J Chachkes; P Fenik; J C Hendricks
Journal:  Sleep       Date:  2001-03-15       Impact factor: 5.849

5.  Mirtazapine, a mixed-profile serotonin agonist/antagonist, suppresses sleep apnea in the rat.

Authors:  D W Carley; M Radulovacki
Journal:  Am J Respir Crit Care Med       Date:  1999-12       Impact factor: 21.405

6.  R-zacopride, a 5-HT3 antagonist/5-HT4 agonist, reduces sleep apneas in rats.

Authors:  D W Carley; H Depoortere; M Radulovacki
Journal:  Pharmacol Biochem Behav       Date:  2001 May-Jun       Impact factor: 3.533

Review 7.  Physiological and pathophysiological implications of upper airway reflexes in humans.

Authors:  T Nishino
Journal:  Jpn J Physiol       Date:  2000-02

8.  Hypoglossal nerve response to 5-HT3 drugs injected into the XII nucleus and vena cava in the rat.

Authors:  P Fenik; H Ogawa; S C Veasey
Journal:  Sleep       Date:  2001-12-15       Impact factor: 5.849

Review 9.  Vanilloid receptor ligands: hopes and realities for the future.

Authors:  A Szallasi
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

10.  Functional role for cannabinoids in respiratory stability during sleep.

Authors:  David W Carley; Sasa Paviovic; Marika Janelidze; Miodrag Radulovacki
Journal:  Sleep       Date:  2002-06-15       Impact factor: 5.849

View more
  10 in total

1.  Intranodose ganglion injections of dronabinol attenuate serotonin-induced apnea in Sprague-Dawley rat.

Authors:  Michael W Calik; Miodrag Radulovacki; David W Carley
Journal:  Respir Physiol Neurobiol       Date:  2013-10-11       Impact factor: 1.931

Review 2.  REM obstructive sleep apnea: risk for adverse health outcomes and novel treatments.

Authors:  Andrew W Varga; Babak Mokhlesi
Journal:  Sleep Breath       Date:  2018-09-19       Impact factor: 2.816

3.  Pharmacotherapy of Apnea by Cannabimimetic Enhancement, the PACE Clinical Trial: Effects of Dronabinol in Obstructive Sleep Apnea.

Authors:  David W Carley; Bharati Prasad; Kathryn J Reid; Roneil Malkani; Hryar Attarian; Sabra M Abbott; Boris Vern; Hui Xie; Chengbo Yuan; Phyllis C Zee
Journal:  Sleep       Date:  2018-01-01       Impact factor: 5.849

4.  Pulmonary C-fiber activation attenuates respiratory-related tongue movements.

Authors:  Kun-Ze Lee; David D Fuller; Ji-Chuu Hwang
Journal:  J Appl Physiol (1985)       Date:  2012-08-30

5.  Effect of Systemic Application of 5-Hydroxytryptamine on Hypoglossal Nerve Discharge in Anesthetized Rats.

Authors:  Xueping Tu; Jinjing Zuo; Ke Hu; Jing Kang; Yongtian Mei; Nian Wang
Journal:  J Mol Neurosci       Date:  2015-06-16       Impact factor: 3.444

6.  Effects of Cannabinoid Agonists and Antagonists on Sleep and Breathing in Sprague-Dawley Rats.

Authors:  Michael W Calik; David W Carley
Journal:  Sleep       Date:  2017-09-01       Impact factor: 5.849

7.  A method of nodose ganglia injection in Sprague-Dawley rat.

Authors:  Michael W Calik; Miodrag Radulovacki; David W Carley
Journal:  J Vis Exp       Date:  2014-11-25       Impact factor: 1.355

8.  Impact of dronabinol on quantitative electroencephalogram (qEEG) measures of sleep in obstructive sleep apnea syndrome.

Authors:  Sarah S Farabi; Bharati Prasad; Lauretta Quinn; David W Carley
Journal:  J Clin Sleep Med       Date:  2014-01-15       Impact factor: 4.062

9.  Proof of concept trial of dronabinol in obstructive sleep apnea.

Authors:  Bharati Prasad; Miodrag G Radulovacki; David W Carley
Journal:  Front Psychiatry       Date:  2013-01-22       Impact factor: 4.157

10.  Intracerebroventricular injections of dronabinol, a cannabinoid receptor agonist, does not attenuate serotonin-induced apnea in Sprague-Dawley rats.

Authors:  Michael W Calik; David W Carley
Journal:  J Negat Results Biomed       Date:  2016-05-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.